Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Anticoagulation in hospitalized patients with COVID-19. Blood 2022 Aug 25;140(8):809-814

Date

06/03/2022

Pubmed ID

35653590

Pubmed Central ID

PMC9361053

DOI

10.1182/blood.2021014527

Scopus ID

2-s2.0-85136551504 (requires institutional sign-in at Scopus site)   13 Citations

Abstract

Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome that may manifest with microvascular and macrovascular thrombosis. Patients with COVID-19 have a higher incidence of venous thromboembolism than other hospitalized patients. Three randomized control trials suggesting benefit of therapeutic heparin in hospitalized noncritically ill patients with COVID-19 have led to conditional guideline recommendations for this treatment. By contrast, prophylactic-dose heparin is recommended for critically ill patients. Unprecedented collaboration and rapidly funded research have improved care of hospitalized patients with COVID-19.

Author List

Baumann Kreuziger L, Sholzberg M, Cushman M

Author

Lisa M. Baumann Kreuziger MD Associate Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Anticoagulants
Blood Coagulation
Heparin
Humans
Venous Thromboembolism